吉非替尼不联合放射治疗日本发生脑转移的EGFR突变肺腺癌患者的二期临床试验

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
2014-01-02 13:51发表评论
期刊: LUNG CANCER2013年11月2期82卷

BACKGROUND: Brain metastases (BM) are a common in patients with lung cancer. Although whole-brain radiation therapy (WBRT) is the standard therapy, it may have a risk of decline in cognitive function of patients. In this study, we evaluated the efficacy of gefitinib alone without radiation therapy for the treatment of patients with BM from lung adenocarcinoma.

 

MATERIALS AND METHODS: Eligible patients had BM from lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Gefitinib was given at 250mg orally once a day until tumor progression or unacceptable toxicity.

 

RESULTS: Forty-one patients were enrolled. The response rate was 87.8%. No patient experienced grade ≥4 toxicity. The median progression-free survival time was 14.5 months (95% CI, 10.2-18.3 months), and the median overall survival time was 21.9 months (95% CI, 18.5-30.3 months). In compared with L858R, exon 19 deletion was associated with better outcome of patients after treatment with gefitinib in both progression-free (p=0.003) and overall survival (p=0.025).

 

CONCLUSION: Favorable response of BM to gefitinib even without irradiation was demonstrated. Exon 19 deletion was both a predictive and prognostic marker of patients with BM treated by gefitinib.

 

结论:对于发生脑转移的EGFR突变肺腺癌患者,即使不联合应用放射治疗,吉非替尼治疗也可以获得良好的缓解。外显子19是脑转移患者接受吉非替尼治疗的预后提示因子。

学科代码:呼吸病学 肿瘤学 放射学   关键词:Metastatic brain tumors; Gefit ,全球精选文摘 爱思唯尔医学网, Elseviermed
来源: 爱思唯尔
爱思唯尔介绍:全球最大的科技医学出版商――爱思唯尔以出版发行高品质的、前沿的科学、技术和医学信息,并保证其满足全世界科技和医学工作者对于信息的需求而著称。现在,公司建立起全球的学术体系,拥有7,000名期刊编辑、70,000名编辑委员会成员、200,000专家审稿人以及500,000名作者,每年出版2,000本期刊和2,200种新书,并拥有17,000种在库图书。 马上访问爱思唯尔网站http://www.elseviermed.cn
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录